Trial Profile

Phase I study of HM12525A in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efinopegdutide (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Hanmi Pharmaceutical

Most Recent Events

09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
05 Jun 2015 New trial record
03 Jun 2015 Results of this study will be presented at the American Diabetes Association's 75th Scientific Sessions, according to a Hanmi Pharmaceutical media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com